Drug intelligence / Profile preview

Lactobacillus rhamnosus CLR2

Development stage: Unknown
Lead developer: Bio-K+
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus rhamnosus CLR2 is a proprietary probiotic bacterial strain developed by Bio-K Plus International (Bio-K+). It is one of the three active live bacterial strains—alongside Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R—that comprise the Bio-K+ probiotic formulation. Marketed as a consumer supplement in North America since 1996, it is available in oral forms such as enteric-coated capsules and fermented dairy or vegan beverages. The strain's mechanism of action is centered on the modulation of the gut microbiota, which helps to restore intestinal balance and prevent dysbiosis. Clinical evidence supports its use in the prevention of Clostridium difficile infection (CDI) and antibiotic-associated diarrhea (AAD), as well as in the management of symptoms associated with irritable bowel syndrome (IBS).

Brand names: Bio-K+
Other names: Lactobacillus rhamnosus CLR2®

Beyond the preview

Go deeper on Lactobacillus rhamnosus CLR2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus rhamnosus CLR2.

Explore the full profile